Related Experiment Video

Updated: Jun 6, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk

Martha L Slattery1, Jennifer S Herrick, Abbie Lundgreen

  • 1Department of Internal Medicine, University of Utah Health Sciences Center, 295 Chipeta Way, Salt Lake City, Utah 84108, USA. marty.slattery@hsc.utah.edu

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|November 12, 2010
PubMed
Abstract

Insights

Genetic variations in the TGF-β signaling pathway, including TGFβ1 and Smad genes, are linked to colon and rectal cancer risk. These findings highlight the pathway's role in cancer development and survival.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The transforming growth factor-beta (TGF-β) signaling pathway is crucial in cellular processes and carcinogenesis.
  • Smad proteins are key mediators of TGF-β signaling.
  • Genetic variations in this pathway may influence cancer risk.

Purpose of the Study:

  • To investigate the association between genetic variations in TGFβ1, TGFβR1, Smad1, Smad2, Smad3, and Smad4 and the risk of colon and rectal cancer.
  • To explore interactions between these genetic variations and environmental factors.
  • To assess the impact of these variations on cancer survival.

Main Methods:

  • A large case-control study was conducted.
  • Participants included 1,444 cases and 1,841 controls for colon cancer, and 754 cases and 856 controls for rectal cancer.
  • DNA was analyzed for genetic variations.

Main Results:

  • Specific variations in TGFβ1 (rs1800469, rs4803455) were associated with colon cancer risk.
  • Several tagSNPs in TGFβR1, Smad2, and Smad3 were linked to colon cancer.
  • Fewer significant associations were found for rectal cancer, but interactions with smoking, aspirin, and estrogen were observed for both.
  • Genetic variations in TGFβ1, TGFβR1, and Smad3 appeared to affect survival.

Conclusions:

  • Genetic variations in the TGF-β signaling pathway are associated with the risk of colon and rectal cancers.
  • The pathway's genetic variations interact with environmental factors, influencing cancer development and outcomes.
  • This study provides insights into the biological pathways involved in colorectal carcinogenesis.

More Related Videos

In vitro Organoid Culture of Primary Mouse Colon Tumors07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...